Henrik Schrøeder

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 401 citations

Life Sciences, Immunology, Oncology +8

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 348 citations · Full text

Medicine, Oncology, Pharmacology +8

A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial

William A. Gray, Koen Keirse, Yoshimitsu Soga et al. · The Lancet · 2018 · 289 citations

Medicine, Cardiology, Surgery +16

Transarterial Chemoembolization for Hepatocellular Carcinoma: Volumetric and Morphologic CT Criteria for Assessment of Prognosis and Therapeutic Success—Results from a Liver Transplantation Center

Thomas J. Vogl, Henrik Schrøeder, Martin Mack et al. · Radiology · 2000 · 164 citations

Medicine, Oncology, Surgery +17

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · Cancers · 2020 · 145 citations · Full text

Medicine, Oncology, Surgery +15